1. Home
  2. SKYE vs FINW Comparison

SKYE vs FINW Comparison

Compare SKYE & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.74

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Logo FinWise Bancorp

FINW

FinWise Bancorp

N/A

Current Price

$17.72

Market Cap

245.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SKYE
FINW
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
44.9M
245.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SKYE
FINW
Price
$0.74
$17.72
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$14.75
$22.00
AVG Volume (30 Days)
475.3K
22.1K
Earning Date
11-10-2025
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.05
Revenue
N/A
$80,198,000.00
Revenue This Year
N/A
$83.64
Revenue Next Year
N/A
$38.08
P/E Ratio
N/A
$16.79
Revenue Growth
N/A
14.76
52 Week Low
$0.70
$13.49
52 Week High
$5.75
$22.49

Technical Indicators

Market Signals
Indicator
SKYE
FINW
Relative Strength Index (RSI) 26.08 45.66
Support Level $0.76 $17.57
Resistance Level $0.95 $18.16
Average True Range (ATR) 0.10 0.53
MACD -0.01 -0.00
Stochastic Oscillator 11.35 41.99

Price Performance

Historical Comparison
SKYE
FINW

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: